Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Sinopharm Hyundai announced that the company's wholly-owned subsidiary Sinopharm Vichida has obtained the registration certificate of lipoic acid API issued by the Ministry of Health and Family Welfare of India and the Ministry of Food and Drug Safety of South Korea. Lipoic acid is a powerful new antioxidant, also known as a universal antioxidant, which can support the activity of glucose in human cells, has a powerful antioxidant effect, can remove free radicals in the body, and help maintain the health of the heart and other internal organs. The lipoic acid API obtained the Indian and Korean registration certificate, marking that the API product can be sold in the Indian and Korean markets, which will have a positive impact on the company's further expansion into the international market.
Sinopharm Rongsheng, a wholly-owned subsidiary of the Company, received the Approval Notice of Drug Supplement Application for Potassium Chloride Injection (10ml: 1.5g) approved by the State Drug Administration, and Sinopharm Rongsheng has approved the approval of potassium chloride injection (specification of 10ml: 1g), and this application is a supplementary application for potassium chloride injection (specification of 10ml: 1.5g) to increase the specifications. Potassium chloride injection is a commonly used clinical drug for the prevention and treatment of hypokalemia, and can also be used to treat premature beats and arrhythmias caused by digitalis poisoning.
![Sinopharm Hyundai's wholly-owned subsidiary API obtained the overseas registration certificate[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)